{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:42:34Z","timestamp":1779144154889,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007913","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["2019DecPR1395"],"award-info":[{"award-number":["2019DecPR1395"]}],"id":[{"id":"10.13039\/501100007913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001923","name":"DH | NIHR | Health Services Research Programme","doi-asserted-by":"publisher","award":["PR-PRU-1217-21601"],"award-info":[{"award-number":["PR-PRU-1217-21601"]}],"id":[{"id":"10.13039\/501100001923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007913","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["2019DecPR1395"],"award-info":[{"award-number":["2019DecPR1395"]}],"id":[{"id":"10.13039\/501100007913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C49757\/A28689"],"award-info":[{"award-number":["C49757\/A28689"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C49757\/A28689"],"award-info":[{"award-number":["C49757\/A28689"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C49757\/A28689"],"award-info":[{"award-number":["C49757\/A28689"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001923","name":"DH | NIHR | Health Services Research Programme","doi-asserted-by":"publisher","award":["PR-PRU-1217-21601"],"award-info":[{"award-number":["PR-PRU-1217-21601"]}],"id":[{"id":"10.13039\/501100001923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It is uncommon for risk groups defined by statistical or artificial intelligence (AI) models to be chosen by jointly considering model performance and potential interventions available. We develop a framework to rapidly guide choice of risk groups in this manner, and apply it to guide breast cancer screening intervals using an AI model. Linear programming is used to define risk groups that minimize expected advanced cancer incidence subject to resource constraints. In the application risk stratification performance is estimated from a case\u2013control study (2044 cases, 1:1 matching), and other parameters are taken from screening trials and the screening programme in England. Under the model, re-screening in 1 year for the highest 4% AI model risk, in 3 years for the middle 64%, and in 4 years for 32% of the population at lowest risk, was expected to reduce the number of advanced cancers diagnosed by approximately 18 advanced cancers per 1000 diagnosed with triennial screening, for the same average number of screens in the population as triennial screening for all. Sensitivity analyses found the choice of thresholds was robust to model parameters, but the estimated reduction in advanced cancers was not precise and requires further evaluation. Our framework helps define thresholds with the greatest chance of success for reducing the population health burden of cancer when used in risk-adapted screening, which should be further evaluated such as in health-economic modelling based on computer simulation models, and real-world evaluations.<\/jats:p>","DOI":"10.1038\/s41746-023-00967-9","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T18:02:11Z","timestamp":1701194531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["An optimization framework to guide the choice of thresholds for risk-based cancer screening"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6327-4357","authenticated-orcid":false,"given":"Adam R.","family":"Brentnall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma C.","family":"Atakpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0908-5595","authenticated-orcid":false,"given":"Harry","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7107-235X","authenticated-orcid":false,"given":"Ruggiero","family":"Santeramo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1990-6684","authenticated-orcid":false,"given":"Celeste","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Cuzick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-3900","authenticated-orcid":false,"given":"Giovanni","family":"Montana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen W.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"967_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2019.11.005","volume":"65","author":"EF Harkness","year":"2020","unstructured":"Harkness, E. F., Astley, S. M. & Evans, D. G. Risk-based breast cancer screening strategies in women. Best Pract. Res. Clin. Obstet. Gynaecol. 65, 3\u201317 (2020).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"967_CR2","doi-asserted-by":"crossref","unstructured":"Shieh, Y. et al. Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial. J. Natl Cancer Inst. 109 (2017).","DOI":"10.1093\/jnci\/djw290"},{"key":"967_CR3","first-page":"317","volume":"37","author":"E Paci","year":"2013","unstructured":"Paci, E., Mantellini, P., Rossi, P. G., Falini, P. & Puliti, D. Tailored Breast Screening Trial (TBST). Epidemiol. Prev. 37, 317\u2013327 (2013).","journal-title":"Epidemiol. Prev."},{"key":"967_CR4","unstructured":"MyPebs. My Personalized Breast Screening \u2013 Full Text View (accessed July 12, 2022) ClinicalTrials.gov."},{"key":"967_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1214\/19-STS729","volume":"35","author":"AR Brentnall","year":"2020","unstructured":"Brentnall, A. R. & Cuzick, J. Risk models for breast cancer and their validation. Stat. Sci. 35, 14\u201330 (2020).","journal-title":"Stat. Sci."},{"key":"967_CR6","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1200\/JCO.21.01337","volume":"40","author":"A Yala","year":"2022","unstructured":"Yala, A. et al. Multi-institutional validation of a mammography-based breast cancer risk model. J. Clin. Oncol. 40, 1732\u20131740 (2022).","journal-title":"J. Clin. Oncol."},{"key":"967_CR7","doi-asserted-by":"crossref","unstructured":"Arasu, V. A. et al. Comparison of mammography AI algorithms with a clinical risk model for 5-year breast cancer risk prediction: an observational study. Radiology 307, e222733 (2023).","DOI":"10.1148\/radiol.222733"},{"key":"967_CR8","doi-asserted-by":"crossref","unstructured":"Damiani, C. et al. Evaluation of an AI model to assess future breast cancer risk. Radiology 307, e222679 (2023).","DOI":"10.1148\/radiol.222679"},{"key":"967_CR9","doi-asserted-by":"crossref","unstructured":"Vachon, C. M. et al. Impact of artificial intelligence system and volumetric density on risk prediction of interval, screen-detected, and advanced breast cancer. J. Clin. Oncol. 41, 3172\u20133183 (2023).","DOI":"10.1200\/JCO.22.01153"},{"key":"967_CR10","doi-asserted-by":"crossref","unstructured":"Yala, A. et al. Toward robust mammography-based models for breast cancer risk. in Science Translational Medicine 13 (American Association for the Advancement of Science Section: Research Article, 2021).","DOI":"10.1126\/scitranslmed.aba4373"},{"key":"967_CR11","doi-asserted-by":"crossref","unstructured":"Halling-Brown, M. D. et al. OPTIMAM mammography image database: a large-scale resource of mammography images and clinical data. Radiol. Artif. Intell. 3, e200103 (2020).","DOI":"10.1148\/ryai.2020200103"},{"key":"967_CR12","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2018.1901","volume":"4","author":"N Pashayan","year":"2018","unstructured":"Pashayan, N., Morris, S., Gilbert, F. J. & Pharoah, P. D. P. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. JAMA Oncol. 4, 1504\u20131510 (2018).","journal-title":"JAMA Oncol."},{"key":"967_CR13","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jval.2017.04.012","volume":"20","author":"E Gray","year":"2017","unstructured":"Gray, E. et al. Evaluation of a stratified National Breast Screening Program in the United Kingdom: an early model-based cost-effectiveness analysis. Value Health 20, 1100\u20131109 (2017).","journal-title":"Value Health"},{"key":"967_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10549-007-9556-1","volume":"107","author":"I Soerjomataram","year":"2008","unstructured":"Soerjomataram, I., Louwman, M. W., Ribot, J. G., Roukema, J. A. & Coebergh, J. W. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res. Treat. 107, 309 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"967_CR15","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1002\/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-H","volume":"75","author":"L Tabar","year":"1995","unstructured":"Tabar, L. et al. Efficacy of breast cancer screening by age new results from the Swedish two-county trial. Cancer 75, 2507\u20132517 (1995).","journal-title":"Cancer"},{"key":"967_CR16","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/s41416-022-01714-9","volume":"126","author":"SW Duffy","year":"2022","unstructured":"Duffy, S. W. et al. The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation. Br. J. Cancer 126, 1355\u20131361 (2022).","journal-title":"Br. J. Cancer"},{"key":"967_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0033-8389(05)70191-3","volume":"38","author":"L Tab\u00e1r","year":"2000","unstructured":"Tab\u00e1r, L. et al. The Swedish two-county trial twenty years later. Radiol. Clin. North Am. 38, 625\u2013651 (2000).","journal-title":"Radiol. Clin. North Am."},{"key":"967_CR18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ijc.33593","volume":"149","author":"SA Khan","year":"2021","unstructured":"Khan, S. A., Hernandez-Villafuerte, K. V., Muchadeyi, M. T. & Schlander, M. Cost-effectiveness of risk-based breast cancer screening: a systematic review. Int. J. Cancer 149, 790\u2013810 (2021).","journal-title":"Int. J. Cancer"},{"key":"967_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41591-021-01599-w","volume":"28","author":"A Yala","year":"2022","unstructured":"Yala, A. et al. Optimizing risk-based breast cancer screening policies with reinforcement learning. Nat. Med. 28, 136\u2013143 (2022).","journal-title":"Nat. Med."},{"key":"967_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/bmj.39308.560069.BE","volume":"335","author":"J Appleby","year":"2007","unstructured":"Appleby, J., Devlin, N. & Parkin, D. NICE\u2019s cost effectiveness threshold. BMJ 335, 358\u2013359 (2007).","journal-title":"BMJ"},{"key":"967_CR21","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s41416-018-0069-y","volume":"118","author":"DP French","year":"2018","unstructured":"French, D. P. et al. Psychological impact of providing women with personalised 10-year breast cancer risk estimates. Br. J. cancer 118, 1648\u20131657 (2018).","journal-title":"Br. J. cancer"},{"key":"967_CR22","doi-asserted-by":"crossref","unstructured":"Pashayan, N. et al. Should age-dependent absolute risk thresholds be used for risk stratification in risk-stratified breast cancer screening? J. Pers. Med. 11, 916 (2021).","DOI":"10.3390\/jpm11090916"},{"key":"967_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08347-w","volume":"21","author":"L McWilliams","year":"2021","unstructured":"McWilliams, L. et al. Extending screening intervals for women at low risk of breast cancer: do they find it acceptable? BMC Cancer 21, 1\u20139 (2021).","journal-title":"BMC Cancer"},{"key":"967_CR24","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.1200\/JCO.2009.22.7041","volume":"27","author":"P Autier","year":"2009","unstructured":"Autier, P., H\u00e9ry, C., Haukka, J., Boniol, M. & Byrnes, G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J. Clin. Oncol. 27, 5919\u20135923 (2009).","journal-title":"J. Clin. Oncol."},{"key":"967_CR25","first-page":"613","volume":"112","author":"C Lee","year":"2020","unstructured":"Lee, C. & McCaskill-Stevens, W. Tomosynthesis Mammographic Imaging Screening Trial (TMIST): an invitation and opportunity for the national medical association community to shape the future of precision screening for breast cancer. J. Natl Med. Assoc. 112, 613\u2013618 (2020).","journal-title":"J. Natl Med. Assoc."},{"key":"967_CR26","first-page":"420","volume":"426","author":"G Launoy","year":"1998","unstructured":"Launoy, G., Duffy, S. W., Prevost, T. C. & Bouvier, V. D\u00e9pistage des cancers, sensibilit\u00e9 du test et sensibilit\u00e9 du programme de d\u00e9pistage. Rev. Epidemiol. Sante Publique 426, 420\u2013426 (1998).","journal-title":"Rev. Epidemiol. Sante Publique"},{"key":"967_CR27","unstructured":"Andersen, M., Dahl, J. & Vandenberghe, L. CVXOPT Python Software for Convex Optimization (accessed April 1, 2022) https:\/\/cvxopt.org (2022)."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00967-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00967-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00967-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T18:07:34Z","timestamp":1701194854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00967-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1038\/s41746-023-00967-9","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R.B. and J.C. declare royalties from CRUK for commercial use of the Tyrer-Cuzick (IBIS) breast cancer risk evaluation algorithm. A.R.B. declares consulting fees from Kings College London. A.R.B. serves on the UK National Screening Committee Research and Methodology subgroup, but this had no role in this manuscript. J.C. declares no non-financial competing interests. All other authors declare no financial or non-financial conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}